Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11096-021-01289-0 http://scihub22266oqcxt.onion/10.1007/s11096-021-01289-0 34076805!8170628!34076805     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34076805&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Int+J+Clin+Pharm 2021 ; 43 (4): 1133-1138 Nephropedia Template TP {{tp|p=34076805|t=2021. Guiding axes for drug safety management of pharmacovigilance centres during the COVID-19 era |pdf=|usr=}}{{34076805}} gab.com Text Guiding axes for drug safety management of pharmacovigilance centres during the COVID-19 era JO: Int J Clin Pharm http://www.kidney.de/pget.php?&tw=1&pmid=34076805 #FOAvip The COVID-19 pandemic presents several challenges to the organisation and workflow of pharmacovigilance centres as a result of the massive increase in reports, the need for quick detection, processing and reporting of safety issues and the management of these within the context of lack of complete information on the disease. Pharmacovigilance centres permanently monitor the safety profile of medicines, ensuring risk management to evaluate the benefit-risk relationship. However, traditional pharmacovigilance approaches of spontaneous reporting, are not suitable in the context of a pandemic; the scientific community and regulators need information on a near real-time point. The aim of this commentary is to suggest six interrelated multidimensional guiding axes for drug safety management by pharmacovigilance centres during the COVID-19 pandemic. This working plan can increase knowledge on COVID-19 and associated therapeutic approaches, support decisions by the regulatory authorities, oppose fake news and promote more efficient public health protection. Twit Text FOAVip Guiding axes for drug safety management of pharmacovigilance centres during the COVID-19 era ????Int J Clin Pharm http://www.kidney.de/pget.php?&tw=1&pmid=34076805 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34076805 #FOAvip English Wikipedia <ref>{{Cite pmid|34076805}}</ref> Guiding axes for drug safety management of pharmacovigilance centres during the COVID-19 era #MMPMID34076805 Ferreira-da-Silva R; Ribeiro-Vaz I; Morato M; Polonia JJ Int J Clin Pharm 2021[Aug]; 43 (4): 1133-1138 PMID34076805show ga The COVID-19 pandemic presents several challenges to the organisation and workflow of pharmacovigilance centres as a result of the massive increase in reports, the need for quick detection, processing and reporting of safety issues and the management of these within the context of lack of complete information on the disease. Pharmacovigilance centres permanently monitor the safety profile of medicines, ensuring risk management to evaluate the benefit-risk relationship. However, traditional pharmacovigilance approaches of spontaneous reporting, are not suitable in the context of a pandemic; the scientific community and regulators need information on a near real-time point. The aim of this commentary is to suggest six interrelated multidimensional guiding axes for drug safety management by pharmacovigilance centres during the COVID-19 pandemic. This working plan can increase knowledge on COVID-19 and associated therapeutic approaches, support decisions by the regulatory authorities, oppose fake news and promote more efficient public health protection. |*Adverse Drug Reaction Reporting Systems/organization & administration[MESH] |*COVID-19 Drug Treatment[MESH] |*Pharmacovigilance[MESH] |Antiviral Agents/*adverse effects/therapeutic use[MESH] |COVID-19/epidemiology[MESH] |Drug-Related Side Effects and Adverse Reactions/epidemiology/etiology[MESH] |Humans[MESH] |Patient Safety[MESH]Guiding axes for drug safety management of pharmacovigilance centres d(epmc).pdf DeepDyve Pubget Overpricing